New combination therapy shows promise in metastatic pancreatic cancer
Headline from MedicalXpress, on the newest of 2 developments
Results from an early-stage clinical trial, published in Nature Communications, showed encouraging outcomes among patients with newly diagnosed cancer whose tumors had spread to distant organs. Most strikingly, one patient experienced a pathologic complete response—meaning no viable cancer cells cou…
MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
FDA approval opens new chapter in pancreatic cancer treatment
Headline from MedicalXpress ·
Newest
New combination therapy shows promise in metastatic pancreatic cancer
In a key clinical trial, patients receiving the drug achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.
The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease. The drug, Revolution Medicines’ Rasonque, or daraxonrasib, was approved for patients with advanced pancreatic cancer who ha…
The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.
Reuters (CNN) — The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
Daraxonrasib made headline earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug — which left his skin bloody and “bubbling” but is giving him more time with his family.
FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the …
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold unde…
The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success wi…
CENTRAL OREGON (KTVZ) -- The Food and Drug Administration approved daraxonrasib Aug. 26, offering a new treatment option for patients with stage 4 metastatic pancreatic cancer. Early research shows the medication doubles average life expectancy for patients with advanced stages of the disease from s…
Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these tumors so deadly.
Rasonque, a pancreatic cancer drug approved by the FDA on Wednesday, doubled the life expectancy of patients with advanced forms of the disease during clinical trials.
Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer.
Showing the first 25 of 46 headlines. ·
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
New combination therapy shows promise in metastatic pancreatic cancer | Since Then
